전기영동 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Electrophoresis Market Size & Trends:

The global electrophoresis market size was estimated at USD 3.29 billion in 2024 and is projected to grow at a CAGR of 5.62% from 2025 to 2030. The growth of the market is attributed to the increasing demand for advanced diagnostic tools, rising investments in biotechnology and healthcare research, and the growing need for efficient protein and nucleic acid analysis. Electrophoresis plays a critical role in various applications such as drug development, disease diagnosis, and research, driving the demand for more sophisticated, high-throughput systems. As the biotechnology, pharmaceutical, and academic sectors continue to focus on precision medicine and genetic research, the need for reliable and efficient electrophoresis systems to separate and analyze proteins, DNA, and RNA is on the rise.

One of the major drivers of growth is the continuous advancements in technology. The development of automated systems, which enhance the efficiency and reproducibility of experiments, is increasing the adoption of these techniques across laboratories worldwide. Additionally, innovations such as high-resolution electrophoresis and the integration of multiplexing capabilities are improving the sensitivity and throughput of these systems. With these advancements, electrophoresis is becoming more accessible and versatile, capable of meeting the evolving demands of various industries, including clinical diagnostics, academic research, and biopharmaceuticals. For instance, the Agilent ProteoAnalyzer system, which is an advanced automated parallel capillary electrophoresis platform designed for protein analysis. This innovative solution streamlines and optimizes the analysis of complex protein mixtures, serving a wide range of industries including pharmaceuticals, biotechnology, food analysis, and academic research.

The rising emphasis on personalized medicine and targeted therapies is another significant factor driving the growth of the market. As healthcare shifts towards more tailored treatments, genetic testing, biomarker identification, and molecular diagnostics have become essential components of medical research and clinical practice. Electrophoresis plays an integral role in these areas, enabling the precise separation and analysis of biomolecules that can be used for disease detection, treatment selection, and monitoring therapeutic efficacy. The increasing demand for genetic testing and the expanding use of electrophoresis in oncology, neurology, and other therapeutic areas are expected to further fuel market growth.

Furthermore, another key factor driving the electrophoresis industry is the increasing demand from clinical laboratories and diagnostic centers. As more clinical laboratories adopt electrophoresis techniques for routine testing and disease diagnosis, particularly in the areas of genetic testing, blood analysis, and protein profiling, the market is experiencing a steady uptick in adoption. Additionally, the rising incidence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, which require precise molecular diagnostic techniques for early detection, further contributes to the demand for electrophoresis-based systems.

Moreover, Pharmaceutical and biotechnology companies are also contributing to the market expansion by investing heavily in research and development (R&D) to discover new drugs and therapies. Electrophoresis is widely used in the drug development process, from screening potential drug candidates to analyzing protein interactions and characterizing therapeutic antibodies. As pharmaceutical companies continue to focus on creating innovative biologic drugs, the demand for advanced systems capable of high-throughput analysis and detailed protein profiling is rising. This growth is particularly evident in areas such as monoclonal antibody development and gene therapy, where electrophoresis is crucial for analyzing complex molecules.

However, the high cost associated with advanced systems and their maintenance is a major restraining factor for growth of the market. These systems, particularly high-throughput or automated platforms, often require significant capital investment, specialized equipment, and skilled personnel for operation, making them less accessible to smaller laboratories or those in emerging markets with limited budgets. Additionally, the complexity of certain electrophoresis techniques can result in longer training periods and potential errors if not properly managed. While these systems offer superior accuracy and efficiency, their cost and operational demands can limit adoption, particularly in low-resource settings. Furthermore, the slow pace of technology adoption in some regions, coupled with regulatory barriers and the need for regulatory approvals, can hinder market growth in certain areas.

Global Electrophoresis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global electrophoresis market report based on product, application, end Use, and region.

• Product Outlook (Revenue, USD Million; 2018 - 2030)
• Electrophoresis Reagents
  • Protein Electrophoresis Reagents
  • Nucleic Acid Electrophoresis Reagents
• Electrophoresis Systems
  • Gel Electrophoresis Systems
  • Capillary Electrophoresis Systems
• Gel Documentation Systems
• Software
• Application Outlook (Revenue, USD Million; 2018 - 2030)
• Research Applications
• Diagnostics Applications
• Quality Control and Process Validation
• End Use Outlook (Revenue, USD Million; 2018 - 2030)
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Hospital and Diagnostic Centers
• Other End Use
• Regional Outlook (Revenue, USD Million; 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
• 2.3. Competitive Insights

Chapter 3. Electrophoresis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Increasing industry academia collaborations
    • 3.2.1.3. Rising need for personalized medicines
    • 3.2.1.4. Technological advancements
    • 3.2.1.5. Increasing funding for genomics and proteomics research
    • 3.2.1.6. Rising number of clinical laboratories
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Untrained personnel
    • 3.2.2.2. Stringent regulations
• 3.3. Electrophoresis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Electrophoresis Market: Product Estimates & Trend Analysis

• 4.1. Global Electrophoresis Market: Product Dashboard
• 4.2. Global Electrophoresis Market: Product Movement Analysis
• 4.3. Global Electrophoresis Market by Product , Revenue
• 4.4. Electrophoresis Reagents
  • 4.4.1. Electrophoresis reagents market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Protein Electrophoresis Reagents
    • 4.4.2.1. Protein electrophoresis reagents market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Nucleic Acid Electrophoresis Reagents
    • 4.4.3.1. Nucleic acid electrophoresis reagents market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Electrophoresis Systems
  • 4.5.1. Electrophoresis systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Gel Electrophoresis Systems
    • 4.5.2.1. Electrophoresis systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Capillary Electrophoresis Systems
    • 4.5.3.1. Capillary electrophoresis systems market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Gel Documentation Systems
  • 4.6.1. Gel documentation systems market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Software
  • 4.7.1. Software market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Electrophoresis Market: Application Estimates & Trend Analysis

• 5.1. Global Electrophoresis Market: Application Dashboard
• 5.2. Global Electrophoresis Market: Application Movement Analysis
• 5.3. Global Electrophoresis Market by Application, Revenue
• 5.4. Research Applications
  • 5.4.1. Research applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Diagnostics Applications
  • 5.5.1. Diagnostics applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Quality Control and Process Validation
  • 5.6.1. Quality control and process validation market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Electrophoresis Market: End Use Estimates & Trend Analysis

• 6.1. Global Electrophoresis Market: Ens-use Dashboard
• 6.2. Global Electrophoresis Market: End Use Movement Analysis
• 6.3. Global Electrophoresis Market by End Use, Revenue
• 6.4. Academic and Research Institutes
  • 6.4.1. Academic and research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Pharmaceutical and Biotechnology Companies
  • 6.5.1. Pharmaceutical and biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hospital and Diagnostic Centers
  • 6.6.1. Hospital and diagnostic centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Other End Use
  • 6.7.1. Other end use market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Electrophoresis Market: Regional Estimates & Trend Analysis by Product, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Bio-Rad Laboratories, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Thermo Fisher Scientific Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Agilent Technologies, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Merck KGaA
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. GE Healthcare
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. QIAGEN
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Lonza Group Ltd.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. PerkinElmer, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Danaher
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Harvard Bioscience, Inc.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Shimadzu Corporation
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives